These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19137767)

  • 1. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
    Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
    J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
    Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
    J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
    Reich K; Langley RG; Lebwohl M; Szapary P; Guzzo C; Yeilding N; Li S; Hsu MC; Griffiths CE
    Br J Dermatol; 2011 Apr; 164(4):862-72. PubMed ID: 21332467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.
    Wolfe F; Michaud K; Anderson J; Urbansky K
    Arthritis Rheum; 2004 Feb; 50(2):372-9. PubMed ID: 14872478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
    Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
    J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
    Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
    J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
    Haitz KA; Kalb RE
    J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
    Gottlieb AB; Gordon K; Giannini EH; Mease P; Li J; Chon Y; Maddox J; Weng HH; Wajdula J; Lin SL; Baumgartner SW
    J Drugs Dermatol; 2011 Mar; 10(3):289-300. PubMed ID: 21369647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
    Gottlieb AB; Leonardi CL; Goffe BS; Ortonne JP; van der Kerkhof PC; Zitnik R; Nakanishi A; Jahreis A
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S92-100. PubMed ID: 16488335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis.
    Leombruno JP; Nguyen GC; Grootendorst P; Juurlink D; Einarson T
    Pharmacoepidemiol Drug Saf; 2011 Aug; 20(8):838-48. PubMed ID: 21688345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
    Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
    Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M; Bonesrønning JH
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
    Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
    Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.